Investigar
This last year has seen incredible progress in the fight to create a world without ALS. The FDA approval of Relyvrio (AMX0035) in 2022 and Qalsody (tofersen) last month are…
A first-of-its-kind stem cell therapy for ALS passes a critical safety benchmark, advancing the search to slow down, reverse and prevent the disease. In a parallel study, investigators are growing…
On April 25, 2023, the US Food and Drug Administration (FDA) announced that Qalsody (tofersen) HAS BEEN APPROVED as a new prescription therapy for the treatment of people with rare…
CAMBRIDGE, Mass., April 25, 2023 (GLOBE NEWSWIRE) — Biogen Inc. (Nasdaq: BIIB) announced today that the U.S. Food and Drug Administration (FDA) has approved QALSODY™ (tofersen) 100 mg/15mL injection for…
Since 1996, the Sheila Essey Award for ALS Research has been presented to acknowledge and honor an individual who is making significant contributions and breakthroughs in the search for the…
NurOwn (BrainStorm Cell Therapeutics) is an investigational therapy made up of autologous mesenchymal stromal cells secreting neurotrophic factors cells (MSC-NTF) for the potential treatment of amyotrophic lateral sclerosis (ALS) and…
Cytokinetics recently announced the discontinuation of Phase 3 Clinical Trial of Reldesemtiv and thanks the people with ALS, caregivers, investigators, and clinical trial staff for their participation in COURAGE-ALS.
The FDA advisory committee vote on tofersen Wednesday was an exciting and critical moment in the ALS community’s efforts to find new treatments and cures. The committee voted unanimously to…
The FDA Peripheral and Central Nervous System Drugs Advisory Committee voted 9-0 that a reduction in plasma neurofilament light (NfL) concentration is “reasonably likely” to predict clinical benefit of tofersen…
By Larry Falivena Larry Falivena is a member of The ALS Association’s Board of Trustees and is living with ALS. Today, he is sharing his unique experience with the disease…
- 1
- 2
- 3
- Siguiente »